As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan. Objective: To ...
This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...
A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback